Prostate cancer screening in Black men in Canada: a case for risk-stratified care

Kikachukwu Otiono BA, Brenda Nkonge BHSc, Oluwatobi R. Olatiye MD MSc, Sean Pierre MD

Cite as: CMAJ 2022 October 24;194:E1411-5. doi: 10.1503/cmaj.220452

Prostate cancer represents the fourth most common cancer and the most common noncutaneous malignant disease among men in Canada. In 2022, it is estimated that prostate cancer will be diagnosed in more than 24,000 people in Canada, representing 20% of all new cancers in men.\(^1\,\text{,}\,2\) The natural history of prostate cancer ranges from an indolent course to a fatal disease, which coincides with a spectrum of management strategies including active surveillance, surgery and radiation therapy. Clinicians continue to grapple with the question of how to identify those with clinically important disease while avoiding overdiagnosis and overtreatment. Black patients present even more of a dilemma since evidence to guide practice in this group is lacking. Data from Canada are minimal, but research from the United States and Europe has shown that the incidence and lifetime risk of developing prostate cancer among Black people are more than double than among their white counterparts.\(^3\,\text{,}\,4\) Current guidelines for prostate cancer have very limited generalizability to Black patients, and Canadian physicians are poorly resourced to provide evidence-based management of their disease. We discuss the current state of evidence and guidance for prostate cancer screening among Black patients in Canada and consider whether guidelines should be re-evaluated to consider differential screening for this high-risk population group.

How are Black people disproportionately affected by prostate cancer?

Mortality and incidence rates of prostate cancer vary widely worldwide by region and source, reflecting variance in screening guidelines and health care resources, as well as ethnocultural differences.\(^5\,\text{–}\,12\) In the Caribbean, prostate cancer incidence rates as high as 304 per 100,000 men have been documented,\(^5\,\text{–}\,7\) compared with 4.7–19.8 per 100,000 in West Africa, 11.5 per 100,000 in Asia, \(-113.6\) per 100,000 in Canada and 111.3 per 100,000 in the US.\(^8\,\text{–}\,10\) A 2020 publication that estimated global cancer burden found the highest mortality rate for prostate cancer in the Caribbean (27.9 per 100,000), followed by Middle, Southern and Western Africa (24.8, 22.0 and 20.2 per 100,000, respectively), and Micronesia and Polynesia (18.8 per 100,000).\(^12\)

Some studies have evaluated epidemiological data for prostate cancer by racial groups in the same region. In England, the incidence rate of prostate cancer was more than twice as high among Black people (rate ratio 2.1) than among white people in 2013–2017.\(^13\) In 2008–2010, the lifetime risk of a Black man in England dying from prostate cancer was 8%, compared with 4% for a white man and 2% for an Asian man.\(^4\) In the US, African American men are more likely to receive a diagnosis of prostate cancer at an advanced stage and twice as likely to die from prostate cancer than white men.\(^10\) The consistently high mortality rates for Black people across many regions may bolster the argument for genetic predisposition.\(^8\) However, environmental and social factors clearly play an important role. Notably, incidence rates of prostate cancer are up to 40 times greater among African American men than men living in African countries.\(^14\)

Broadly speaking, racial disparities in prostate cancer diagnosis and mortality have been attributed to several factors, including gaps in health care access,\(^15\) the underrepresentation of Black patients in clinical trials\(^16\) and genetic ancestry.\(^17\) Recent evidence shows that, even with low-grade prostate cancer, African American patients tend to display more aggressive disease characteristics and experience an earlier transformation from latent to invasive prostate cancer than their white counterparts.\(^18\) In addition, research into the genetics of prostate cancer has shown that Black people have an increased likelihood of

Key points

- Black people with prostate cancer face a complex interplay of structural barriers such as inadequate health education, underrepresentation in clinical trials and reduced access to treatment — all of which contribute to poor health outcomes.
- Current screening guidelines do not provide specific guidance to clinicians treating Black patients, which likely contributes to their increased risk of developing and dying of prostate cancer.
- Implementing targeted screening programs in Canada for Black people could result in earlier detection and treatment, and lower risk of death.
- Any attempt to alleviate racial disparities in health requires not just isolated changes such as screening and treatment guidelines, but also a wider understanding of systemic racism and its impacts on patient outcomes.
inheriting high-risk loci associated with prostate cancer, which points to the possibility of genetic susceptibility in this group.\textsuperscript{19,20} Appendix 1, available at www.cmaj.ca/lookup/doi/10.1503/cmaj.220452/tab-related-content, summarizes the evidence exploring various factors contributing to racial disparities in prostate cancer that we used in this review.

**How do the social determinants of health affect prostate cancer outcomes for Black patients in Canada?**

According to the 2016 Census, Black people constitute 3.5\% of the Canadian population and are expected to constitute 5.6\% of the total population by 2036.\textsuperscript{21} Black Canadians are a diverse population that includes migrant communities, as well as descendants of enslaved people.\textsuperscript{22}

Systemic racism refers to political, legal, health care and economic systems that disenfranchise certain groups. Structural racism highlights the structures that uphold such systems, such as laws, policies and deeply held beliefs.\textsuperscript{23} The terms are sometimes used interchangeably. Many Black patients in Canada encounter structural barriers at several stages of the health care system, including primary care, diagnostic processes and prognosis.\textsuperscript{24} These barriers are underpinned by centuries of systemic inequalities affecting racialized communities, which inevitably elevates their risk for poor health outcomes. The stress of encountering anti-Black racism in the health care system is further intensified by the underrepresentation of Black people among physicians, as well as implicit racial biases exhibited by health care professionals.\textsuperscript{25,26}

Clinicians in Canada should recognize that historical and ongoing systemic racism likely plays a role in the disproportionate burden of prostate cancer in Black communities and that socioeconomic barriers in health care may significantly affect prostate cancer outcomes for Black men. For example, research has shown that lower socioeconomic status contributes to poorer outcomes for patients with prostate cancer.\textsuperscript{27,28} Many studies have shown that poverty is racialized in Canada.\textsuperscript{29,30} In terms of nonfinancial barriers, inadequate health education and decreased health-seeking behaviours may contribute to adverse health outcomes for Black people with prostate cancer. Black people often lack prerequisite information to make informed decisions about prostate cancer screening,\textsuperscript{31} which is worsened by medical mistrust and limited discussions with health care providers that are culturally appropriate.\textsuperscript{32}

A recent cohort study found no increase in prostate cancer-specific mortality among Black people in Canada after adjusting for nonbiological differences such as socioeconomic status and access to health care.\textsuperscript{33} This finding contradicted earlier studies that proposed genetic differences as a major cause for elevated risks of prostate cancer in Black people.\textsuperscript{19,20} It is, however, likely that genetic ancestry and societal barriers intersect, and further research is required to draw out such nuances. Nonetheless, understanding and addressing the social determinants of health is critical in closing the gap in health inequities in prostate cancer screening, diagnosis, treatment and survival.

**How do guidelines account for racial disparities in prostate cancer outcomes?**

The most recent guideline from the Canadian Task Force on Preventive Health Care recommends against routine prostate-specific antigen (PSA) screening for men of all ages, but states that the greatest benefit from screening is likely in those aged 55–69 years.\textsuperscript{34} The guideline identifies and reports the increased risk of prostate cancer among Black people, but does not provide specific guidance on managing this increased risk, stating that “there is no trial data showing that benefits or harms of screening differ in these populations, as compared to men in the general population.”\textsuperscript{34} Such a general statement fails to acknowledge the long history of exclusion of Black patients from clinical trials or any nuanced consideration of targeted screening guidelines for this population.

The 2022 guideline from the Canadian Urological Association (CUA) on prostate cancer summarizes 3 randomized controlled trials that constitute credible Level 1 evidence for prostate cancer screening.\textsuperscript{35} The CUA emphasizes the importance of shared decision-making between patients and physicians in choosing screening and treatment methods that balance risk and benefit. According to the CUA guideline, should a patient decide to undergo screening, PSA testing should start at age 50 years in the general population or at age 45 years for people at an increased risk (Grade C recommendation). However, Black people are not included in this high-risk category, despite the evidence to suggest that this population is at a higher risk of metastatic disease and death. No explicit mention is made of racial disparities in prostate cancer diagnosis and mortality in the 2022 CUA guideline, except for in a few footnotes. Similarly, the US Preventative Services Task Force (USPSTF) recommendations allude to racial disparities in prostate cancer outcomes without providing any specific guidance for this group.\textsuperscript{36}

**Should Black people in Canada be screened differently for prostate cancer?**

The potential harms related to the overdiagnosis of prostate cancer — which include invasive biopsies, numerous medical visits, increased patient anxiety and increased health care costs — are important to note.\textsuperscript{37,38} However, should providers weigh the risk of overdiagnosis the same for Black people as for the general population?

Clinical trials of prostate cancer screening and treatment have not adequately included Black participants.\textsuperscript{39,40} Both the CUA and USPSTF guidelines on prostate cancer refer to data from the prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. However, this study reported that only 4\% of participants were non-Hispanic Black men, which limits the external validity of the findings.\textsuperscript{40} This is in the context of other studies that have shown that, when compared with white patients, Black patients in the US are more likely to have a larger tumour volume,\textsuperscript{41} elevated initial PSA levels,\textsuperscript{42} longer time intervals between screenings\textsuperscript{43} and earlier transformation to clinically important disease.\textsuperscript{18,19} If Black people have been shown to present with more aggressive and
advanced disease in PSA-eligible populations, applying average-risk guidelines to this population ignores their lived reality. Moreover, the European Randomized Study of Screening for Prostate Cancer found that PSA screening is helpful in reducing the incidence of metastatic prostate cancer. Since Black people are at overall higher risk of developing metastatic prostate cancer, this further supports raising the question of whether PSA screening for Black people should start at an earlier age.

To show the impact of risk-stratified screening, a 2022 study used age- and year-specific data from the Surveillance, Epidemiology, and End Results database and US census data to evaluate the harm-to-benefit tradeoffs for Black people undergoing PSA screening, compared with people of other racial and ethnic groups. The analysis showed that the numbers needed to diagnose and treat are more favourable for Black people compared with the general population, even in the least optimistic scenario (i.e., assuming that only half of the decrease in mortality rates is attributable to screening). An earlier microsimulation study showed that annual PSA screening in Black men aged 45—69 years reduced mortality (26%–29%) with a lower rate of overdiagnosis. The risks related to increased screening remain a concern; however, the emergence of new protocols for biopsy and imaging, as well as active surveillance for patients with low-risk disease, may reduce the risk of overdiagnosis and overtreatment.

Of note, the development of new adjunctive strategies for early screening for prostate cancer may play an important role in ameliorating the risk of overdiagnosis and overtreatment for high-risk patients. Recent publications from the CUA and Cancer Care Ontario suggest that biopsy-naïve patients at an elevated risk of clinically important prostate cancer may benefit from multiparametric magnetic resonance imaging before a biopsy. Other strategies for acquiring additional information about a patient’s risk of cancer include interpreting their PSA velocity, percent-free PSA, and biomarker panels — all of which may be implemented in the future for refined care of Black patients at risk for prostate cancer. With regards to screening guidelines, insofar as the CUA suggests prostate cancer screening should start at age 45 years for men at increased risk of developing prostate cancer, we consider that it is reasonable to include Black people in the high-risk group as they are at demonstrably high risk of diagnosis and death from prostate cancer. Supporting this suggestion is guidance from the European Association of Urology (EAU) that includes Black people in the high-risk category that begins screening at age 45 years, instead of age 50 years for the general population.

Why do we need better Canadian data?

Although studies have examined the under-representation of Black people in Canada in other screening programs and drug trials, similar research on prostate cancer clinical trials in Canada is lacking. The dearth of race-based data in Canada results in an over-reliance on data from the US and other countries. Although we may anticipate that the trends are similar in Canada, Black people in Canada are demographically different and face different barriers. For example, 2016 Census data show that 52.0% of Black people living in Canada are immigrants, while 44.3% are Canadian citizens by birth. Conversely, only 10% of the Black population in the US is foreign-born. The unique challenges facing the descendants of enslaved Africans in the US are not interchangeable with the experiences of Black immigrants and refugees in Canada, and vice versa. Insofar as a large proportion of Black people in Canada are foreign-born, any analysis of racial disparities in Canadian health care should consider the impact of migrant trauma, language barriers, cultural differences and poor health education.

Racial differences in health outcomes are an important consideration in health research as a means of identifying populations that require more evaluation, attention and intervention. We acknowledge that “race” is a social construct based on phenotype and cultural differences, and should not be considered as a biological variable, which would obscure the complex interactions of structural barriers, socioeconomic status, genetics and environmental exposures. As such, racial disparities in the incidence and mortality rates of prostate cancer among Black people are multifactorial and require multiple solutions.

Conclusion

Black people in Canada may be genetically predisposed to more aggressive prostate cancer, yet they also face socioeconomic barriers and lack access to robust health education, which affect their chances of early detection of disease. Moreover, they are less likely to receive optimal treatment after receiving a cancer diagnosis.

We consider that, in line with the EAU guideline that recommends screening Black people in Europe at an earlier age and the substantial existing evidence of poor outcomes, Canadian guidelines should include Black patients in the high-risk group that is eligible for prostate cancer screening at an earlier age, such as 45 years. Better health education for Black people is also required, as is careful attention and discussion of evidence when making shared decisions with Black patients. Gaps in the literature should prompt further study. The collection of race-based data and evaluation of diversity in clinical trials should be mandatory. Although it is beyond the scope of this article to outline a screening and diagnostic algorithm for Black people that would include the granularities of PSA testing, biopsy or radiographic imaging, we would argue that rigorous data collection and research are required to support a much-needed review of guidelines for prostate cancer screening to better support the health of Black people in Canada. Tackling structural racism is no easy task, and will require decolonization, institutional changes and antiracism education. Clinicians must play a role in closing the gaps.
References

1. Canadian cancer statistics. Toronto: Canadian Cancer Society. Available: https://cancer.ca/en/research/cancer-statistics/canadian-cancer-statistics (accessed 2022 Feb. 22).

2. Brenner DR, Poirier A, Woods RR, et al.; Canadian Cancer Statistics Advisory Committee. Projected estimates of cancer in Canada in 2022. CMAJ 2022;194:E601-7.

3. Powell IU. Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol 2007;177:444-9.

4. Lloyd T, Hounsome L, Mehay A, et al. Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008–2010. BMC Med 2015;13:171.

5. Bunker CH, Patrick AL, Koney BR, et al. High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey. Prostate Epidemiol Biomarkers Prev 2002;11:726-9.

6. Gibson TN, Blake G, Hanchard B, et al. Age-specific incidence of cancer in Kingston and St Andrew, Jamaica, 1998–2002. West Indian Med J 2008;57:81-9.

7. Glover FE Jr, Coffey DS, Douglas LL, et al. The epidemiology of prostate cancer in Jamaica. J Urol 1998;159:1894-6, discussion 1886-7.

8. Rawla P. Epidemiology of prostate cancer. World J Oncol 2019;10:63-80.

9. Lagacé F, Ghazawi FM, Le M, et al. Incidence and mortality of prostate cancer in Canada during 1992–2010. Curr Oncol 2021;28:978-90.

10. Cancer stat facts: prostate cancer. Bethesda (MD): National Cancer Institute. Available: https://seer.cancer.gov/statfacts/html/prost.html (accessed 2022 Mar. 9).

11. Seraphin TP, Joko-Fru WY, Kamate B, et al. Rising prostate cancer incidence in sub-Saharan Africa: a trend analysis of data from the African cancer registry network. Cancer Epidemiol Biomarkers Prev 2021;30:158-65.

12. Sung H, Ferlay J, Siegel RL, et al. Cancers of incidence and mortality worldwide for 38 cancers in 165 countries. CA Cancer J Clin 2021;71:209-49.

13. Delon C, Brown KF, Payne NWS, et al. Differences in cancer incidence by broad ethnic group in England, 2013–2017. Br J Cancer 2022;126:1765-73.

14. Chu LW, Ritchey J, Devesa SS, et al. Prostate cancer incidence rates in Africa. Prostate Cancer 2011;111:947870.

15. DesR LT, Hartman HE, Mahal BA, et al. Association of Black race with prostate cancer-specific and other-cause mortality. JAMA Oncol 2019;5:975-83.

16. Rencso EM, Bazli LA, McKay RR, et al. Diversity of enrollment in prostate cancer clinical trials: current status and future directions. Cancer Epidemiol Biomarkers Prev 2020;29:1374-80.

17. Rayford W, Bekacs AT, Alger J, et al. Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences. Commun Biol 2021;4:670.

18. Deka R, Courtney PT, Parsons JK, et al. Association between African American race and clinical outcomes in men treated for low-risk prostate cancer with active surveillance. JAMA 2020;324:1747-54.

19. Powell IU, Bock CH, Ruterbusch JJ, et al. Evidence supports a faster growth rate and/or earlier transformation to clinically significant disease in Black than in White American men, and influences racial progression and mortality disparity. J Urol 2010;183:1379-6.

20. Conti DV, Wang K, Sheng X, et al.; PRACTICAL/EPELL Consortium. Two novel susceptibility loci for prostate cancer in men of African ancestry. J Natl Cancer Inst 2017;109:djx084.

21. Maheux H, Do D. Diversity of the Black population in Canada: an overview. Cat no r 89-657-X2019002. Ottawa: Statistics Canada; 2019. Available: https://www150.statcan.gc.ca/n1/pub/89-657-x/89-657-x2019002-eng.htm (accessed 2022 Feb. 17).

22. Whitfield HA. North to bondage: loyalist slavery in the Maritimes. Vancouver: University of British Columbia Press; 2016.

23. Braveman PA, Arkin E, Proctor D, et al. Systemic and structural racism: definitions, examples, health damages, and approaches to dismantling. Health Aff (Millwood) 2022;41:171-8.

24. Dryden O, Nkowu O. Time to dismantle systemic anti-Black racism in medicine in Canada. CMAJ 2021;193:E55-7.

25. Black Health Alliance, Health Commons Solutions Lab. Black experiences in health care symposium: bringing together community and health systems for improved health outcomes. Antigonish (NS): National Collaborating Centre for Determinants of Health; 2020. Available: https://ncchda.ca/resources/entry/black-experiences-in-health-care-symposium-bringing-together-community-and (accessed 2022 Feb. 17).
50. Haider MA, Brown J, Chin JLK, et al. Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer: a Cancer Care Ontario updated clinical practice guideline. *Can Urol Assoc J* 2022;16:16-23.

51. Haider MA, Brown J, Yao X, et al. Multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer: an updated systematic review. *Clin Oncol (R Coll Radiol)* 2021;33:e599-612.

52. Van Poppel H, Roobol MJ, Chapple CR, et al. Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: European association of urology position and recommendations for 2021. *Eur Urol* 2021;80:703-11.

53. Nnorom O, Findlay N, Lee-Foon NK, et al. Dying to learn: a scoping review of breast and cervical cancer studies focusing on black Canadian women. *J Health Care Poor Underserved* 2019;30:1331-59.

54. Dickmann LJ, Schutzman JL. Racial and ethnic composition of cancer clinical drug trials: How diverse are we? *Oncologist* 2018;23:243-6.

55. Tamir C. The growing diversity of Black America: 46.8 million people in the U.S. identify as Black. Washington (DC): Pew Research Center; 2021. Available: https://www.pewresearch.org/social-trends/2021/03/25/the-growing-diversity-of-black-america/ (accessed 2022 Feb. 17).

56. George U, Thomson MS, Chaze F, et al. Immigrant mental health, a public health issue: looking back and moving forward. *Int J Environ Res Public Health* 2015;12:13624-48.

57. King RU, Este DC, Yohani S, et al. Actions needed to promote health equity and the mental health of Canada’s Black refugees. *Ethn Health* 2022;27:1518-36.

58. Salami B, Denga B, Taylor R, et al. Access to mental health for black youths in Alberta. *Health Promot Chronic Dis Prev Can* 2021;41:245-53.

59. Datta G, Siddiqi A, Lofers A. Transforming race-based health research in Canada. *CMAJ* 2021;193:E99-100.

**Competing interests:** None declared.

This article has been peer reviewed.

**Affiliations:** Michael G. DeGroote School of Medicine (Otiono), Bio-medical Discovery and Commercialization (Nkonge) and Division of Plastic Surgery (Olaiya), Faculty of Health Sciences, McMaster University, Hamilton, Ont.; Division of Urology (Pierre), Queensway Carleton Hospital, Ottawa, Ont.

**Contributors:** All of the authors conceived and designed the work. Kikachukwu Otiono, Brenda Nkonge and Oluwatobi Olaiya contributed to the literature review. Kikachukwu Otiono and Brenda Nkonge drafted the manuscript. All of the authors contributed to revising it critically for important intellectual content, gave final approval of the version to be published and agreed to be accountable for all aspects of the work.

**Content licence:** This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

**Correspondence to:** Kikachukwu Otiono, kika.otiono@medportal.ca